A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Trial Profile

A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel; Doxorubicin; Gemcitabine; Irinotecan; Paclitaxel; Vinorelbine
  • Indications Adenocarcinoma; Breast cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms PembroPlus
  • Most Recent Events

    • 08 Nov 2017 Results (n=17) evaluating the safety and efficacy of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma patients, were published in the Investigational New Drugs.
    • 08 Aug 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
    • 08 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top